- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study from NCPA sheds new light on med synchronization programs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
PHILADELPHIA — Lannett announced that it has begun shipping three generic drugs that recently were approved by the Food and Drug Administration.
The generic drug maker said that it has shipped diethylpropion tablets in the 25-mg strength; phentermine hydrochloride capsules in the 37.5-mg strength and loxapine capsules in 5-mg, 10-mg, 25-mg and 50-mg strengths.
“Sales of the three products augment and strengthen our growing product offering, and we expect will be solid contributors to both sales and profits in fiscal 2012," Lannett president and CEO Arthur Bedrosian said.